| GLP-1RAs improve glycaemic control, reduce patient weight and improve patient-reported outcomes when administered as monotherapy or add-on therapy to other glucose-lowering drugs |
| GLP-1RAs reduce, or at least not increase, the risk of major cardiovascular events |
| GLP-1RAs are generally well tolerated with a very low intrinsic risk of hypoglycaemia |
| Once-weekly administration of GLP-1RAs may improve treatment adherence and satisfaction relative to more frequent treatment |
| Consider clinical and administration differences between-GLP-1RAs and patient preferences when individualizing treatment |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.